ClinicalTrials.gg
CompletedNCT00224107Updated Jul 12, 2011Results posted

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

A Phase 3 interventional study of Silodosin and Placebo in Benign Prostatic Hyperplasia (BPH), sponsored by Watson Pharmaceuticals. Completed at 43 sites in United States. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-07-12.

Sponsored by Watson Pharmaceuticals (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
461
Allocation
Randomized
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing silodosin in Prostatic Hyperplasia — 4 open to participants now, 4 under way, none of them phase 3. silodosin · Prostatic Hyperplasia.

Enrollment
5th of 19
461 · median 141
Started
2005
with 2 others
Phase 3
4 of 19
none open now
Registered
1st of 19
by date
Lead sponsor
4 of 19
Watson Pharmaceuticals

Among the 19 studies testing silodosin in Prostatic Hyperplasia, this one is the 5th largest by enrollment, is one of 3 that started in 2005, is one of 4 in phase 3, and was the 1st registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

4 of the 19 studies testing silodosin in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About silodosin

silodosin: first FDA approval 2008 (RAPAFLO), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing silodosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.

Read the detailed description

This will be a multi-center, double-blind, placebo controlled, parallel, 12 week treatment trial in men with signs and symptoms of benign prostatic hyperplasia. The following procedures are utilized: physical exams, electrocardiograms, clinical laboratory tests, vital signs, the International Prostate Symptom Score, maximum urine flow rate, pharmacokinetics, adverse events, concomitant medications, quality of life, and compliance.

03

Conditions studied

  • Benign Prostatic Hyperplasia (BPH)

Browse trials for

Keywords

  • Benign prostatic hyperplasia, BPH, alpha blocker
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males in good general health and at least 50 years of age, with symptoms of moderate to severe benign prostatic hyperplasia.

Exclusion criteria

Exclusion Criteria:

  • Medical conditions that would confound the efficacy evaluation.
  • Medical conditions in which it would be unsafe to use an alpha-blocker.
  • The use of concomitant drugs that would confound the efficacy evaluation.
  • The use of concomitant drugs that would be unsafe with this alpha-blocker.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
461 participants (actual)

Study arms

  • Experimental
    Silodosin

    Silodosin 8 mg once daily with food

    Drug: Silodosin

  • Placebo comparator
    placebo

    Matching Placebo capsule once daily with food

    Other: Placebo

Interventions

  • 8 mg daily for 12 weeks

    Also known as: Rapaflo

  • OtherPlacebo

    1 capsule daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. International Prostate Symptom Score (IPSS)

    Change from baseline In IPSS at Week 12. IPSS uses a 0 to 35 scale; 0 best, 35 worse symptoms

    Time frame: 12 weeks

Secondary outcomes

  1. Maximum Urine Flow Rate (Qmax)

    Change from baseline in maximum urine flow rate (Qmax)at Week 12

    Time frame: 12 weeks

07

Results

Posted Dec 3, 2009

Participant flow

Participant flow — Overall Study
MilestoneSilodosinPlacebo
Started233228
Completed202214
Not completed3114
Withdrew: Adverse event206
Withdrew: Protocol violation23
Withdrew: Withdrawal by subject14
Withdrew: Lack of efficacy20
Withdrew: Lost to follow-up40
Withdrew: Physician decision10
Withdrew: Other11

Outcome measures

PrimaryInternational Prostate Symptom Score (IPSS)

Change from baseline In IPSS at Week 12. IPSS uses a 0 to 35 scale; 0 best, 35 worse symptoms

Time frame:
12 weeks
Reported as:
Mean · Units on a 0 to 35 scale
International Prostate Symptom Score (IPSS)
Units on a 0 to 35 scaleSilodosinPlacebo
Baseline IPSS21.5 ± 5.3821.4 ± 4.91
Change from Baseline in IPSS at Week 12-6.5 ± 6.73-3.6 ± 5.85
SecondaryMaximum Urine Flow Rate (Qmax)

Change from baseline in maximum urine flow rate (Qmax)at Week 12

Time frame:
12 weeks
Reported as:
Mean · mL/sec
Maximum Urine Flow Rate (Qmax)
mL/secSilodosinPlacebo
Baseline Qmax9.0 ± 2.609.0 ± 2.85
Change from Baseline in Qmax at Week 122.2 ± 4.311.2 ± 3.81

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Silodosin—3/233 (1.3%)116/233 (49.8%)
Placebo—3/228 (1.3%)24/228 (10.5%)
Most frequent serious events
Most frequent serious events
EventSilodosinPlacebo
Myocardial infarctionCardiac disorders2/2331/228
Cerebral haemorrhageNervous system disorders0/2331/228
DiverticulitisInfections and infestations0/2331/228
Small intestinal obstructionGastrointestinal disorders0/2331/228
Cardiac failure congestiveCardiac disorders1/2330/228
Enterococcal bacteremiaInfections and infestations1/2330/228
PneumoniaInfections and infestations1/2330/228
RadiculopathyNervous system disorders1/2330/228
Respiratory failureRespiratory, thoracic and mediastinal disorders1/2330/228
Most frequent other events
Most frequent other events
EventSilodosinPlacebo
Retrograde ejaculationReproductive system and breast disorders68/2332/228
HeadacheNervous system disorders8/2333/228
NasopharyngitisInfections and infestations5/2337/228
DiarrhoeaGastrointestinal disorders7/2331/228
DizzinessNervous system disorders6/2334/228
Nasal congestionRespiratory, thoracic and mediastinal disorders6/2330/228
Orthostatic hypotensionVascular disorders6/2335/228
InsomniaNervous system disorders5/2330/228
SinusitisInfections and infestations5/2332/228

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SilodosinPlaceboTotal
<=18 years000
Between 18 and 65 years136130266
>=65 years9798195
Age Continuous
Age Continuous(years)SilodosinPlaceboTotal
Mean64.4 ± 7.9464.0 ± 7.8464.2 ± 7.88
Sex: Female, Male
Sex: Female, Male(Participants)SilodosinPlaceboTotal
Female000
Male233228461
Region of Enrollment
Region of Enrollment(participants)SilodosinPlaceboTotal
United States233228461
08

Study locations

43 sites
  • Huntsville, Alabama, United States
  • Tucson, Arizona, United States
  • Anaheim, California, United States
  • Culver City, California, United States
  • Irvine, California, United States
  • La Jolla, California, United States
  • Long Beach, California, United States
  • Newport Beach, California, United States
  • San Diego, California, United States
  • Aurora, Colorado, United States
  • Wheat Ridge, Colorado, United States
  • Waterbury, Connecticut, United States
  • Aventura, Florida, United States
  • Clearwater, Florida, United States
  • Coral Gables, Florida, United States
  • Pensacola, Florida, United States
  • Marietta, Georgia, United States
  • Chicago, Illinois, United States
  • Peoria, Illinois, United States
  • Des Moines, Iowa, United States
  • St. Joseph, Michigan, United States
  • Edina, Minnesota, United States
  • Missoula, Montana, United States
  • Las Vegas, Nevada, United States
  • Bay Shore, New York, United States
  • Garden City, New York, United States
  • Manhasset, New York, United States
  • New York, New York, United States
  • Staten Island, New York, United States
  • Williamsville, New York, United States
  • Charlotte, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Bethany, Oklahoma, United States
  • Portland, Oregon, United States
  • Lancaster, Pennsylvania, United States
  • Greer, South Carolina, United States
  • Dallas, Texas, United States
  • Salt Lake City, Utah, United States
  • Lakewood, Washington, United States
  • Tacoma, Washington, United States
  • Milwaukee, Wisconsin, United States
09

References and documents

Publications

  • Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009 Jun;181(6):2634-40. doi: 10.1016/j.juro.2009.02.034. Epub 2009 Apr 16. PubMed 19371887 ↗
  • Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2013 Jan;189(1 Suppl):S122-8. doi: 10.1016/j.juro.2012.11.020. PubMed 23234617 ↗
  • Roehrborn CG, Kaplan SA, Lepor H, Volinn W. Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis. 2011 Jun;14(2):143-8. doi: 10.1038/pcan.2010.46. Epub 2010 Dec 7. PubMed 21135869 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2005, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2005
First posted
Sep 22, 2005
Start
May 2005
Primary completionActual
Aug 2006
CompletionActual
Aug 2006
Results first posted
Dec 3, 2009
Last update
Jul 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00224107
First posted
Sep 22, 2005
Start date
May 2005
Primary completion
Aug 2006
Completion
Aug 2006
Results posted
Dec 3, 2009
Last update
Jul 12, 2011

Study contacts

Lawrence Hill, PharmD, RPh
study director · Watson Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Silodosin

Start the discussion